COHEN DAVID I has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1943. It filed its patents most often in United States, Canada and Israel. Its main competitors in its focus markets biotechnology, pharmaceuticals and environmental technology are RESPONSIF GMBH, WEINER DAVID B and VAXIION THERAPEUTICS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | Canada | 2 | |
#3 | Israel | 1 | |
#4 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Environmental technology | |
#4 | Measurement | |
#5 | Computer technology | |
#6 | Foods and drinks | |
#7 | Consumer goods |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Climate change adaptation technologies | |
#6 | Analysing materials | |
#7 | Enzymes | |
#8 | Electric digital data processing | |
#9 | Corsets | |
#10 | Bioinformatics |
# | Name | Total Patents |
---|---|---|
#1 | Cohen David I | 18 |
Publication | Filing date | Title |
---|---|---|
US2018016305A1 | DAGRS: Directed Antigonists to Cancer Cell Growth Signals | |
US2016022810A1 | Method for Treating Cancers by Alternating Immunotherapeutics and Directly Oncolytic Therapeutics | |
US2006160183A1 | Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease | |
US2005226890A1 | Tat-based vaccine compositions and methods of making and using same | |
US2007248618A1 | Tat-Based vaccine Compositions and Methods of Making and Using Same | |
US2005208482A1 | Tat-based immunomodulatory compositions and methods for their discovery and use | |
US2008044435A1 | Tat-Based Tolerogen Compositions and Methods of Making and Using Same | |
WO0112220A1 | Non-immunosuppressant hiv tat | |
US2362974A | Brassiere | |
CA432219A | Brassiere |